Verastem gains on duvelisib Priority Review

Verastem Inc. (NASDAQ:VSTM) added $0.32 (11%) to $3.22 on Monday after it said FDA accepted and granted Priority Review to an NDA seeking full

Read the full 240 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE